{
    "nct_id": "NCT03483324",
    "official_title": "A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord",
    "inclusion_criteria": "* Patients must have received some immunosuppressive chemotherapy in the preceding 3 months.\n* Acute myelogenous leukemia (AML):\n\n  1. Complete first remission (CR1) at high risk for relapse\n  2. Complete second remission (CR2).\n  3. No documented myelofibrosis at screening marrow biopsy\n* Acute lymphoblastic leukemia (ALL):\n\n  1. Complete first remission (CR1) at high risk for relapse\n  2. Complete second remission (CR2).\n* Other acute leukemias that are of ambiguous lineage or of other types\n* Any acute leukemia with marrow aplasia or without adequate count recovery.\n* Myelodysplastic Syndrome (MDS)\n* Karnofsky score > 70 %.\n* Calculated creatinine clearance > 60 ml/min.\n* Bilirubin < 1.5 mg/dL, ALT < 3 x upper limit of normal\n* Pulmonary function (FVC, FEV1 and corrected DLCO) > 50% predicted.\n* Left ventricular ejection fraction > 50%.\n* Albumin > 3.0 g/dL.\n* Negative antiviral serology:\n* Negative human immunodeficiency virus (HIV) antibody.\n* Negative human T-lymphotropic virus (HTLV)-1 and 2 antibodies.\n* Negative hepatitis B surface antigen (HBsAg) and undetectable hepatitis B virus (HBV) DNA\n* Negative hepatitis C virus (HCV) antibody or negative HCV ribonucleic acid (RNA)\n* For female subjects of childbearing potential:\n\n  1. A negative serum pregnancy test\n  2. Willing to use contraception throughout the study period.\n* Male subjects must be willing to use a recommended method of contraception throughout the study period, and to refrain from sperm donation throughout the study period.\n* Two appropriate CB units identified for the subject.\n* In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's cancer.\n* Willingness and ability to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.\n* Evidence of a signed informed written consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 60 Years",
    "exclusion_criteria": "* Pregnancy or breastfeeding.\n* Current active, uncontrolled bacterial, viral, or fungal infection\n* Prior allogeneic or autologous HCT at any time.\n* Active malignancy other than the one for which AB-110 transplant is being performed within 12 months of enrollment.\n* Any identified and available 10/10 HLA-matched related donor or 10/10 HLA-matched unrelated donor.\n* Have evidence of recipient donor specific anti-HLA antibodies.\n* Active central nervous system (CNS) disease at time of screening.\n* Documented allergy to DMSO, mouse or bovine proteins, or iron.\n* Subject has other conditions that in the opinion of the investigator would place the subject at increased risk for toxicity by participation in the study.\n* Psychiatric condition making the patient unlikely to comply with protocol therapy, required tests and follow-up.",
    "miscellaneous_criteria": ""
}